cariprazine

Details

Files
Generic Name:
cariprazine
Project Status:
Complete
Therapeutic Area:
Schizophrenia
Manufacturer:
AbbVie Corporation
Call for patient/clinician input open:
Brand Name:
Vraylar
Project Line:
Reimbursement Review
Project Number:
SR0827-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of schizophrenia in adults.
Submission Type:
Resubmission
Fee Schedule:
Schedule A
Indications:
For the treatment of schizophrenia in adults.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input openNovember 08, 2023
Call for patient/clinician input closedJanuary 08, 2024
Clarification:

- Patient input submission received from Schizophrenia Society of Canada

Submission receivedDecember 20, 2023
Submission acceptedJanuary 11, 2024
Review initiatedJanuary 12, 2024
Draft CADTH review report(s) provided to sponsor for commentApril 08, 2024
Deadline for sponsors commentsApril 17, 2024
CADTH review report(s) and responses to comments provided to sponsorMay 09, 2024
Expert committee meeting (initial)May 22, 2024
Clarification:

Recommendation deferred to June 26, 2024 CDEC meeting

Draft recommendation issued to sponsorJuly 10, 2024
Draft recommendation posted for stakeholder feedbackJuly 18, 2024
End of feedback periodAugust 01, 2024
Final recommendation issued to sponsor and drug plansAugust 15, 2024
Final recommendation postedSeptember 03, 2024
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)August 29, 2024
CADTH review report(s) postedJanuary 16, 2025